A Review of Local Therapy for the Management of Cystoid Macular Edema in Uveitis

Asia Pac J Ophthalmol (Phila). 2021 Jan-Feb;10(1):87-92. doi: 10.1097/APO.0000000000000352.

Abstract

Uveitic macular edema is a significant cause of visual impairment in most uveitis types. Treatment options of uveitis have advanced remarkably in recent years. Up to now, corticosteroids remain the mainstay of treatment. Nonsteroidal immunomodulators, and recently the biologic agents, which can reinforce efficacy and enable discontinuation or reduction of steroids to maintenance doses, are becoming increasingly popular in the management of uveitic macular edema. Several medications can be used in intraocular delivery and more and more sustained releasing implants are being developed. This review will briefly focus on the review of local therapy for the management of cystoid macular edema in uveitis, as many of these novel approaches are currently being evaluated in clinical trials.

Publication types

  • Review

MeSH terms

  • Adrenal Cortex Hormones
  • Clinical Trials as Topic
  • Humans
  • Macular Edema* / drug therapy
  • Macular Edema* / etiology
  • Uveitis* / complications
  • Uveitis* / therapy

Substances

  • Adrenal Cortex Hormones